Patent ID: 8900820

Claim:
A method of determining if a patient diagnosed with non-small cell lung cancer (NSCLC) is a responder to treatment with gefitinib comprising: a. obtaining lung cancer tissue from the patient diagnosed with non-small cell lung cancer; b. determining the levels of expression in the lung cancer tissue or lung cancer cells of the four proteins: p70S6K comprising the amino acid sequence of SEQ ID NO. 17, phospho-S6 comprising the amino acid sequence of SEQ ID NO. 18, phospho-mTOR comprising the amino acid sequence of SEQ ID NO. 20, and EGFR comprising the amino acid sequence of SEQ ID NO. 25; and c. determining that the patient is a responder to treatment with an EGFR-TK inhibitor if the levels of expression of p70S6K, phospho-S6, phospho-mTOR and EGFR are elevated in the lung cancer tissue or lung cancer cells as compared to the corresponding levels in normal lung tissue or normal lung cells.